ALS News Today

September 20, 2021September 20, 2021

Out of ‘Stealth’ Mode, QurAlis Expects First QRL-201 Trial in 2022

ALS News Today

QurAlis is advancing the development of QRL-201, its “groundbreaking” lead treatment candidate for amyotrophic lateral sclerosis (ALS), and expects to initiate its first clinical trial in late 2022. The stem ... Read more

September 17, 2021September 17, 2021

Two Tests May Be Better Than One at Predicting Survival

ALS News Today

The two most common measures used in amyotrophic lateral sclerosis (ALS) assessments — the ALS functional rating scale-revised (ALSFRS-R) and forced vital capacity (FVC) — can predict survival more accurately ... Read more

September 16, 2021September 16, 2021

Phase 1b Trial of Oral DNL343 in ALS Patients Begins Dosing

ALS News Today

A Phase 1b clinical trial evaluating the safety and pharmacological profile of DNL343, Denali Therapeutics’ investigational oral therapy, in adults with amyotrophic lateral sclerosis (ALS) has started dosing participants. The ... Read more

September 15, 2021September 15, 2021

Amylyx Plans to File for Approval of AMX0035 in US

ALS News Today

Amylyx Pharmaceuticals plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the coming months for approval of its investigational oral therapy AMX0035 ... Read more

September 15, 2021September 15, 2021

New Institute Aims to Leave No Rare Disease Patient Behind

ALS News Today

A newly launched non-profit institute is seeking to advance research, and the development of new therapies, for people with rare diseases — a patient community with some of the largest ... Read more

September 14, 2021September 14, 2021

Clene Soon Will Complete Phase 2 Trial Testing CNM-Au8

ALS News Today, COVID-19 News

The last patient visit has been completed in Clene’s Phase 2 trial investigating the potential of CNM-Au8 — which uses nanotechnology to prevent the loss of motor neurons — for ... Read more

September 13, 2021September 13, 2021

Dosing Begins in Phase 2 Trial of AL001 in ALS With C9orf72 Mutations

ALS News Today

A first patient has been dosed in a Phase 2 clinical trial testing Alector’s investigational antibody AL001 as a treatment for amyotrophic lateral sclerosis (ALS) associated with C9orf72 mutations. The trial is ... Read more

September 10, 2021September 10, 2021

Group Focuses on Rare Disease Clinical Trial Participation

ALS News Today

Participation in clinical trials exposes rare disease patients to financial, physical, and emotional pressures, according to the results of a patient focus group series. “Rare disease trial participants are running ... Read more

September 10, 2021September 10, 2021

Speech Study Using AI Technology to Spot ALS Biomarkers

ALS News Today

A technology based on artificial intelligence is helping to spot biomarkers and document the progression of amyotrophic lateral sclerosis (ALS) in a large speech study being conducted by EverythingALS. The ... Read more

September 9, 2021September 9, 2021

ProMIS to Validate TDP-43 Antibodies for ALS Treatment

ALS News Today

ProMIS Neurosciences is advancing the development of antibodies against toxic TDP-43 protein clumps for the treatment of amyotrophic lateral sclerosis (ALS), the company announced. Through lab and animal tests, ProMIS said ... Read more

September 8, 2021September 8, 2021

Health Canada to Review AMX0035 as ALS Treatment

ALS News Today

Health Canada has agreed to review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). “We are pleased that our submission has been accepted ... Read more

September 7, 2021September 7, 2021

NIH Grants $10M to US Trial of Stentrode Brain Implant for Paralysis

ALS News Today

A $10-million grant from the National Institutes of Health (NIH) will help fund the first U.S.-based clinical trial of Synchron’s Stentrode, a wireless brain device, implanted without open brain surgery, ... Read more

September 3, 2021September 3, 2021

Patients, Caregivers Asked to Help Adira in Choosing Grant Awards

ALS News Today

The Adira Foundation is inviting people with neurodegenerative diseases and their caregivers to join a grant proposal review committee. A nonprofit foundation, its mission is to unite people affected by some of ... Read more

September 2, 2021September 2, 2021

Companies Focus on ALS in Partnering AI, Drug Discovery Skills

ALS News Today

Bringing artificial intelligence (AI) to the development of small molecule therapies for amyotrophic lateral sclerosis (ALS) and other neurological diseases is the goal of a business partnership in Asia. The ... Read more

September 1, 2021September 1, 2021

Subtle Changes in MicroRNA-218 May Fuel ALS

ALS News Today

Dropping the levels of microRNA-218 (miR-218) — a small molecule that regulates the activity of other genes — below a certain threshold leads to severe motor neuron damage, paralysis, and ... Read more